Repatha
Payments companies reported to CMS as associated with Repatha. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Repatha, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Repatha
These are the largest totals companies reported as associated with Repatha. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Nihar Desai | New Haven, CT | Cardiovascular Disease | $361,944.71 |
| Michael Cobble | Sandy, UT | Family Medicine | $342,212.48 |
| Payal Kohli | Aurora, CO | Cardiovascular Disease | $280,721.91 |
| Rajkumar Sugumaran | Phoenix, AZ | Cardiovascular Disease | $240,143.38 |
| Peter Toth | Sterling, IL | Family Medicine | $212,670.73 |
| Nathan Trentham | Etowah, TN | Internal Medicine | $201,805.47 |
| Dharmesh Patel | Southaven, MS | Cardiovascular Disease | $191,897.39 |
| John Isaac | Houston, TX | Interventional Cardiology | $183,256.90 |
| William Cromwell | Raleigh, NC | Family Medicine | $167,917.35 |
| Samir Bhatt | Santa Maria, CA | Interventional Cardiology | $165,284.95 |
Prescribed Repatha?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.